A5082510607- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal and Anal Carcinomas
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Inflammatory mediators and NSAID effects
- Radiomics and Machine Learning in Medical Imaging
- Skin Protection and Aging
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- Tryptophan and brain disorders
- Chromatin Remodeling and Cancer
- Gut microbiota and health
- Immune cells in cancer
- Multiple Myeloma Research and Treatments
Institut Gustave Roussy
2017-2025
Université Paris-Saclay
2017-2025
Centre National de la Recherche Scientifique
2017-2025
Cancer Research UK Manchester Institute
2024
Université Paris-Sud
2021
La Ligue Contre le Cancer
2021
Stabilité génétique et oncogenèse
2017-2018
Abstract Gut microbiota composition influences the clinical benefit of immune checkpoints in patients with advanced cancer but mechanisms underlying this relationship remain unclear. Molecular mechanism whereby gut responses is mainly assigned to microbial metabolites. Short-chain fatty acids (SCFA) are produced large amounts colon through bacterial fermentation dietary fiber. We evaluate mice and treated anti-CTLA-4 blocking mAbs whether SCFA levels related outcome. High blood butyrate...
Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, responsiveness MMRD cancers to αPD-1 therapy is highly heterogeneous, and origins this variability remain not fully understood. 4T1 CT26 mouse tumor cell lines were inactivated for gene Msh2, leading a massive accumulation mutations after serial passages cells. Insertions/deletion events mutation load evaluated by whole...
Background: MSI-H/dMMR is considered the first predictive marker of efficacy for immune checkpoint inhibitors (ICIs). However, around 39% cases are refractory and additional biomarkers needed. We explored prognostic value pretreatment LIPI in patients treated with ICIs, including identification fast-progressors. Methods: A multicenter retrospective study metastatic tumors ICIs between April 2014 May 2019 was performed. calculated based on dNLR > 3 LDH upper limit normal. groups were good...
Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate highly heterogeneous across MMRD tumors. The objective study to find a score that predicts anti-PD-(L)1 in Sixty-one various origin tumors and treated were retrospectively included this study. An expert radiologist annotated all present at baseline first evaluation CT-scans by circumscribing them on their largest axial axis (single slice),...
Abstract Melanoma is the deadliest form of skin cancer. Treatment with immune checkpoint blockade (ICB) has transformed outcomes. However, half melanoma patients do not derive long-term benefit. Side-effects ICB are frequent, and typically managed by systemic or topical treatment corticosteroids, widely known for their immunosuppressive effects. clinical data contradictory as to effect on prognosis receiving that also receive some studies suggesting a negative steroid use, others no even...
Abstract Mismatch repair deficiency leads to high mutation rates and microsatellite instability (MSI-H), associated with immune infiltration responsiveness immunotherapies. In early stages, MSI-H tumors generally have a better prognosis lower metastatic potential than microsatellite-stable (MSS) tumors, especially in colorectal cancer. However, advanced lose this survival advantage for reasons that remain unclear. We developed syngeneic mouse model of MSI cancer by knocking out the MMR gene...